[HTML][HTML] The eXpeRience registry: the 'real-world'effectiveness of omalizumab in allergic asthma
GJ Braunstahl, CW Chen, R Maykut, P Georgiou… - Respiratory …, 2013 - Elsevier
Omalizumab has demonstrated therapeutic benefits in controlled clinical trials. Evaluation of
outcomes in real-world clinical practice is needed to provide a complete understanding of …
outcomes in real-world clinical practice is needed to provide a complete understanding of …
'Real‐life'effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review
I Abraham, A Alhossan, CS Lee, H Kutbi… - Allergy, 2016 - Wiley Online Library
Abstract We reviewed 24 'real‐life'effectiveness studies of omalizumab in the treatment of
severe allergic asthma that included 4117 unique patients from 32 countries with significant …
severe allergic asthma that included 4117 unique patients from 32 countries with significant …
[HTML][HTML] Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: study of efficacy and safety
AH Mansur, S Srivastava, V Mitchell, J Sullivan… - Respiratory …, 2017 - Elsevier
Omalizumab has been shown to be an effective add-on therapy for patients with
uncontrolled severe persistent allergic asthma. There has been a steady accumulation of …
uncontrolled severe persistent allergic asthma. There has been a steady accumulation of …
The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study
M Bhutani, WH Yang, J Hébert, F de Takacsy, JL Stril - PLoS One, 2017 - journals.plos.org
Background Omalizumab is a non-steroidal medication indicated for the treatment of poorly
controlled moderate-to-severe allergic asthmatics. This observational study examines the …
controlled moderate-to-severe allergic asthmatics. This observational study examines the …
“Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis
A Alhossan, CS Lee, K MacDonald… - The Journal of Allergy and …, 2017 - Elsevier
Background After the approval of omalizumab for severe allergic asthma, a total of 25
studies have evaluated the effectiveness of omalizumab under “real-life” conditions of …
studies have evaluated the effectiveness of omalizumab under “real-life” conditions of …
Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis
T Lai, S Wang, Z Xu, C Zhang, Y Zhao, Y Hu, C Cao… - Scientific reports, 2015 - nature.com
Currently, limited information is available to clinicians regarding the long-term efficacy of
omalizumab treatment for allergic asthma. In this report, we aimed to (i) systematically …
omalizumab treatment for allergic asthma. In this report, we aimed to (i) systematically …
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
R Buhl, M Soler, J Matz, R Townley… - European …, 2002 - Eur Respiratory Soc
The ability of omalizumab, an anti-immnoglobulin‐E agent, to maintain long‐term disease
control in patients with moderate-to-severe allergic asthma was investigated in a 24‐week …
control in patients with moderate-to-severe allergic asthma was investigated in a 24‐week …
Omalizumab: a review of its use in patients with severe persistent allergic asthma
K McKeage - Drugs, 2013 - Springer
Omalizumab (Xolair®) is a subcutaneously administered monoclonal antibody that targets
circulating free IgE and prevents its interaction with the high-affinity IgE receptor (FCεRI) …
circulating free IgE and prevents its interaction with the high-affinity IgE receptor (FCεRI) …
Omalizumab is effective in the long-term control of severe allergic asthma
BQ Lanier, J Corren, W Lumry, J Liu… - Annals of Allergy …, 2003 - Elsevier
BACKGROUND: Previous reports show that addition of omalizumab to standard therapy
reduces asthma exacerbations and simultaneously decreases use of inhaled corticosteroids …
reduces asthma exacerbations and simultaneously decreases use of inhaled corticosteroids …
[HTML][HTML] Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: a nine-year study
D Di Bona, I Fiorino, M Taurino, F Frisenda… - Respiratory …, 2017 - Elsevier
Abstract Background Randomized Controlled Trials showed that omalizumab exhibited a
good safety and tolerability profile in patients with moderate-to-severe asthma. However …
good safety and tolerability profile in patients with moderate-to-severe asthma. However …